Comparison of Human Gut microbiota-derived consortium complex with rifaximin and rifaximin for irritable bowel syndrome patients

Comparison of Human Gut microbiota-derived consortium complex with rifaximin and rifaximin for irritable bowel syndrome patients: A open-label, prospective, randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0008556

Enrollment

Registered

2023-06-26

Start date

2023-10-05

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Combination of rifaximin and Human Gut microbiota-derived consortium complex group Human Gut microbiota-derived consortium complex contained multiple strains of the Lactobacillus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients (19 years or older) who met the Rome IV criteria for the diagnosis of IBS were eligible to participate.

Exclusion criteria

Exclusion criteria: The exclusion criteria were previous abdominal surgery except appendectomy and Caesarian section, inflammatory bowel syndrome, and concurrent severe illness (cancer, cardiovascular or pulmonary disease). In addition, patients who had used antipsychotics, antibiotics, and probiotics within the four weeks were also excluded.

Design outcomes

Primary

Measure	Time frame
Change of IBS Symptom Severity assessed with the IBS Severity Scoring System (50 points or more decrease) : Assessed using IBS SSS Questionnaire	—

Secondary

Measure	Time frame
Change of abdominal pain Severity assessed with the IBS Severity scoring System (10 points or more decrease) : Assessed using IBS SSS Questionnaire;Change of Irritable Bowel Syndrome Quality of Life Score (10 points or more decrease) : Assessed using IBS- QOL Questionnaire	—

Countries

Korea, Republic of

Contacts

Public ContactChang Kyo Oh

Hallym University Medical Center-Kangnam

ckdryekd@gmail.com+82-2-829-5120

Outcome results